Question 1

What was the main finding of the study?

Accepted Answer

Mim8 significantly reduced annualized bleeding rates in Hemophilia A patients compared to both on-demand treatment (up to 98.7% reduction) and prior clotting factor prophylaxis (up to 54.0% reduction).

Question 2

How is Mim8 administered?

Accepted Answer

It is given as a subcutaneous injection (under the skin) either once a week or once a month, which is much easier than traditional intravenous infusions.

Question 3

Is Mim8 safe for Hemophilia A patients?

Accepted Answer

Yes, the trial showed it was well-tolerated. There were no blood clots (thromboembolic events) or neutralizing antibodies, and minor injection-site reactions occurred in only 2.6% of doses.

Does Mim8 (Denecimig) Reduce Bleeding Rates in Hemophilia A Patients?